Suppliers / Shandong New Time Pharmaceutical

Shandong New Time Pharmaceutical

China Updated 9 July 2026

Shandong New Time Pharmaceutical is an API and finished-dose manufacturer based in China. It holds 34 active US drug master files and 8 valid CEPs. Its filings concentrate with US FDA, TMDA (TZ) and EFDA (ET). Its GMP standing is certified by EMA, MFDS (Korea) and US FDA, among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 9 July 2024 as VAI.

34
active US DMFs
8
valid CEPs
3
registered plants 1 with an FDA FEI number
20
filings across 6 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
4 of 4 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 9 July 2024 VAI US FDA
  • 11 May 2018 VAI US FDA
  • 25 March 2016 VAI US FDA
  • 23 August 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
SHANDONG, China Not on file
Linyi, China Not on file
China, China 3006704412

What they file, and where

Molecule Regulators Docs
Isoflurane EDQM, SFDA (Saudi Arabia), US FDA 4
Potassium Clavulanate EDQM, SFDA (Saudi Arabia) 4
Sevoflurane EDQM, SFDA (Saudi Arabia), US FDA 4
Clavulanic Acid US FDA 3
Zoledronic Acid EDQM, US FDA 3
Epirubicin US FDA 2
Ketorolac US FDA 2
Milrinone SFDA (Saudi Arabia), US FDA 2
Montelukast EDQM, US FDA 2
Bempedoic Acid US FDA 1
Show all 30 molecules on file
Cabazitaxel US FDA 1
Carfilzomib US FDA 1
Dalfampridine US FDA 1
Daunorubicin US FDA 1
Decitabine US FDA 1
Elagolix US FDA 1
Esomeprazole US FDA 1
Fosaprepitant US FDA 1
Gadoteridol US FDA 1
Gimeracil US FDA 1
Isosorbide Mononitrate EDQM 1
Lasmiditan US FDA 1
Linagliptin US FDA 1
Mycophenolate Mofetil US FDA 1
Orlistat US FDA 1
Oteracil US FDA 1
Sitagliptin US FDA 1
Tadalafil US FDA 1
Tegafur US FDA 1
Temsirolimus US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 14 1
TMDA (TZ) 2 1
EFDA (ET) 1 None
JFDA (JO) 1 None
UZPHARM (UZ) 1 None
MINSA (CR) 1 None
EMA None 3
MFDS (Korea) None 2
ANVISA (Brazil) None 1

Comparing suppliers?

Choose your molecules and target markets. Shandong New Time Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 2 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 9 July 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates